{"entity":{"id":"ascletis","kind":"company","name":"Ascletis Pharma","aka":["Ascletis Pharmaceuticals Co., Ltd.","Ascletis Pharma Inc.","歌礼制药"],"tldr":"Ascletis is a Hangzhou biotech listed in Hong Kong, first known for hepatitis C antivirals, which sponsors phase 3 cancer trials among its liver-disease and metabolic programmes.","summary":"Ascletis Pharma, headquartered in Hangzhou and listed in Hong Kong, began with direct-acting antivirals for hepatitis C in China and has since moved into liver disease, metabolic disease and oncology, including a PD-L1 antibody programme. ClinicalTrials.gov lists Ascletis as lead sponsor of a phase 3 cancer trial. Its phase 3 cancer trial tests the fatty acid synthase inhibitor ASC40 (denifanstat, TVB-2640) with bevacizumab in recurrent glioblastoma (NCT05118776), and it has a phase 1 trial of the oral PD-L1 inhibitor ASC61 in advanced solid tumours (NCT05287399).","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.ascletis.com"},{"label":"ClinicalTrials.gov: trials led by Ascletis Pharmaceuticals Co., Ltd.","url":"https://clinicaltrials.gov/search?lead=Ascletis%20Pharmaceuticals%20Co.%2C%20Ltd."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q140045748"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["hcc","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["asc40"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hangzhou","country":"CN","companyType":"biotech","website":"https://www.ascletis.com","stage":"public","investors":[],"funding":[]},"route":"/companies/ascletis/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"asc40","kind":"drug","name":"ASC40","route":"/drugs/asc40/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct05118776","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","route":"/trials/nct05118776/"}]}}